小细胞肺癌分子研究和治疗领域的新进展

文章预览

SCI 7 August 2024 Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer (Nature Reviews Clinical Oncology, IF: 81.1) Triparna Sen, Nobuyuki Takahashi, Subhamoy Chakraborty, Naoko Takebe, Amin H. Nassar, Nagla A. Karim, Sonam Puri & Abdul Rafeh Naqash CORRESPONDENCE TO: triparna.sen@mssm.edu; abdulrafeh-naqash@ouhsc.edu Abstract 摘要 Small-cell lung cancer (SCLC) has traditionally been considered a recalcitrant cancer with a dismal prognosis, with only modest advances in therapeutic strategies over the past several decades. Comprehensive genomic assessments of SCLC have revealed that most of these tumours harbour deletions of the tumour-suppressor genes TP53 and RB1 but, in contrast to non-small-cell lung cancer, have failed to identify targetable alterations. The expression status of four transcription factors with key roles in SCLC pathogenesis defines distinct molecular subtypes of the disease, potentially enabling specific therapeutic ………………………………